The pattern of response to interferon alpha (α-IFN) predicts sustained response to a 6-month α-IFN and ribavirin retreatment for chronic hepatitis C

Journal of Hepatology

Volumn 33, Issue 1, 2000, Pages 128-134

  Cavalletto, Luisa ^a   Chemello, Liliana ^a   Donada, Carlo ^b   Casarin, Pietro ^c   Belussi, Fabio ^d   Bernardinello, Elisabetta ^a   Marino, Filippo ^e   Pontisso, Patrizia ^a   Gatta, Angelo ^a   Alberti, Alfredo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Pordenone Hospital   (Italy)

^c Sacile Hospital   (Italy)

^d Le Grazie Venezia Hospital   (Italy)

^e Department of Pathology Padova ^*  (Italy)

Author keywords

Antiviral drug therapy; Combination therapy; Hepatitis treatment; IFN and ribavirin

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033919502     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80169-5     Document Type: Article

References (21)

1. Poynard T, Leroy V, Cohard M, Thevelot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
2. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-interferon in chronic hepatitis C. Hepatology. 22:1995;700-706.
3. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo GL. Therapy of hepatitis C: re-treatment with alpha-interferon. Hepatology. 26:1997;137S-142S.
4. NIH Consensus Development Conference. Management of hepatitis C. Hepatology. 26:1997;1S-153S.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b and ribavirin for 48 weeks or for 24 weeks versus interfeon α2b and placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
6. McHutchinson J, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
7. Davis G, Esteban-Mur R, Rustgi VK, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 339:1998;1493-1499.
8. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin and interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 107:1994;812-817.
9. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or not-sustained response to interferon alone. J Med Virol. 46:1995;43-47.
10. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and interferon-α alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat. 4:1997;185-191.
11. Schalm S, Hansen B, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: a meta-analysis of individual patient data from European centers. J Hepatol. 26:1997;961-966.
12. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 79:1998;2381-2391.
13. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol. 23:1995;8-12.
14. Lai MY, Kao JH, Yang P, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin and interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 111:1996;1307-1312.
15. Reichard O, Norkrans G, Frydén A, Braconier JH, Sonnerborg A, Weiland O. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-87.
16. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat FZ, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 22:1995;696-699.
17. Pontisso P, Ruvoletto MG, Nicoletti M, Tisminetzky S, Gerotto M, Levrero M. Distribution of three major HCV genotypes in Italy. A multicentric study of 495 patients with chronic hepatitis C. J Viral Hepatitis. 2:1995;33-38.
18. Brouwer JT, Hansen B, Niesters HGM, Schalm SW. Early prediction of reponse in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV-RNA at 4 weeks versus ALT. J Hepatol. 30:1999;192-198.
19. Schalm SW, Weiland O, Hansen B, Milella M, Lai MY, Hollander A, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individuals patient data of six controlled trials. Gastroenterology. 117:1999;408-413.
20. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P, et al. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis who failed to respond to, or relapse after, interferon alpha therapy: a randomized trial. Am J Med. 107:1999;112-118.
21. Wedemeyer H, Jaeckel E, Wedemeyer J, Franck H, Schueler A, Trautwein C, et al. Re-treatment of chronic hepatitis C with interferon alpha and ribavirin in non-responders to interferon alpha monotherapy: analysis of own experience and review of the literature. Z Gastroenterol. 36:1998;819-827.